Target intelligence / Profile preview

Nicotinic acetylcholine receptor alpha3 beta4 subunit-containing (nAChR α3β4)

Target
nAChR α3β4
Molecular classification
Ion channel, Ligand-gated ion channel, Receptor
01

Overview

The **Nicotinic acetylcholine receptor alpha3 beta4 subunit-containing** (nAChR α3β4) is a pentameric ligand-gated ion channel composed of combinations of α3 and β4 subunits[1][3][5]. It mediates fast synaptic transmission in autonomic ganglia by allowing Na⁺ and K⁺ influx upon activation by acetylcholine or other agonists. This receptor is highly expressed in the peripheral nervous system (autonomic ganglia, adrenal medulla) and certain brain regions linked to reward and addiction. The α3β4 subtype serves as a relay between central and peripheral nervous systems and is pivotal for modulating autonomic tone and reward circuitry. Antagonists selective for α3β4, such as AT-1001 or 18-MC, demonstrate utility in reducing drug-seeking behaviors and are under investigation as therapies for substance use disorders, especially nicotine addiction[2][3][5]. The receptor’s structural details have been resolved using cryo-EM, revealing key aspects of ligand selectivity and ion permeation[1][5][7].

Other names
Alpha3 beta4 nicotinic receptorα3β4 receptorGanglion-type nicotinic receptorNeuronal nicotinic acetylcholine receptor α3β4
02

Mechanism of action

Agonist (e.g. acetylcholine, nicotine) binding induces channel opening, resulting in increased Na⁺ and K⁺ ion permeability[3][5]. Competitive antagonists bind to the receptor’s ligand-binding site and block activation (e.g. DHβE, SR16584)[3]. Non-competitive antagonists inhibit function via allosteric/ion channel block (e.g. mecamylamine, AT-1001, 18-MC, bupropion)[2][3].

03

Biological functions

Signal transductionNeurotransmissionModulation of autonomic nervous systemRegulation of reward pathways
04

Disease associations

Addiction (substance use disorder, nicotine dependence)Neuropsychiatric disordersPotential role in cardiovascular disease
05

Safety considerations

Potential for autonomic side effects (such as cardiovascular effects, due to peripheral ganglionic action)CNS effects including mood and reward modulation, abuse liability with agonistsRisk of drug interactions impacting autonomic nervous system function or neurotransmission[4][2]
06

Interacting drugs

Nicotine

17 more in the full profile.

Beyond the preview

Go deeper on Nicotinic acetylcholine receptor alpha3 beta4 subunit-containing (nAChR α3β4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinic acetylcholine receptor alpha3 beta4 subunit-containing (nAChR α3β4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call